Financial Results Q3 2018 - YouTube

Hello everyone we're here in Basel for our executive committee meeting and I'm

joined by some of my executive committee colleagues where for the first time we're gonna try a

little bit of a different approach to giving

you an update on our quarterly performance.

We had a strong performance in Q3 both from an operational standpoint

but also from an innovation standpoint.

Now I'd like to start with Liz Barrett our CEO of Novartis Oncology to give you some

perspectives on the milestones we achieved at Novartis Oncology, Liz.

Thanks Vas and I tell you Q3 was an exciting quarter for us as the whole year has

been, but three things really stand out one is we've got the approval in Europe

for Kymriah for relapsed refractory DLBCL as well as for pediatric and young

adult ALL which I think you know patients and physicians have been

waiting for this therapy so we're really excited to be able to bring that to them

the second was our adjuvant approval in adjuvant melanoma for Taf/Mek you know

just another milestone in that businesses, that business continues to

exceed our expectations and continues to grow and that brings another therapy for

patients in the adjuvant setting of melanoma and lastly we've got some great

data on BYL719 which is our alpha-specific PI3K inhibitor and we're really excited

about that as well and you'll see that the data will actually be presented this

weekend in the presidential presentation at ESMO so stay tuned to hear

more about that.

Great progress and when you think of a CAR-T therapy cell

and gene therapy in building new breakthrough innovation platforms is

critical to our strategy here at Novartis.

One of the important areas where we made progress as well was in

gene therapies as well as other elements of the pharmaceuticals pipeline and I

wanted to hand it over to Paul Hudson to say a few words about that.

Yeah we did Vas and it's great to mention it so

with a AVXS-101 in SMA 1 we simultaneously filed in Japan, Europe and

the US which is a tremendous accomplishment by a great team of people

for those that don't know SMA, SMA 1 many of those infants won't make it to

the second birthdays.

We had CHMP positive opinion for Luxturna

and then beyond that we submitted for secondary progressive MS a difficult

to treat stage of the illness both in Europe and the US with siponimod.

And then of course we launched now our CGRP Aimovig in migraine whilst

we are pleased from a commercial perspective we are delighted that what

is an over trivialized disease is getting attention and a huge unmet need

Is having something brought to it, so tremendous quarter.

So as you can see great progress from an innovative

medicines perspective on our core portfolio as well as building cell and

gene therapy platforms to drive future growth.

We also had an important quarter in Sandoz where we're building the

world's leading biosimilars business with some important milestones so I will hand

it to Richard Francis to talk a bit about those.

Thanks Vas Thanks Vas yes so quarter three saw some important

developments we continued to build out this largest portfolio maintaining

our leadership position so we got a CHMP opinion in two areas firstly on adalimumab

a very important product so we're excited to be bringing that to the

market hopefully in the next quarter and really taking

the burden off the health care systems from a financial point of view

and bringing early access to that therapy and then the final one is pegfilgrastim

which is another very critical therapy, an important therapy that

I know Liz and her team know a lot about so looking forward to bringing that to

the market as well.

That's great and I'm excited to see what's possible

now as biosimilars become more and more an important part of the healthcare solution

for healthcare systems around the world.

So now let's turn to our operational performance where we've had I think a strong quarter where

we drove excellent performance so, Harry.

Thanks Vas and as you say innovation is translating into sales performance

clearly and Paul mentioned that I have to say something about Entresto and

Cosentyx, Entresto more than doubled versus prior year, Cosentyx

fantastic quarter there together with great growth

in oncology and biosimilars and Sandoz so 6 percent constant currency quarter

the highest quarter growth of this year and that's translating with our productivity

and efficiency efforts to 9 percent core operating income growth, which is very

important for all of us and our investors, because this financial

performance gives us then the right to reinvest in fantastic medicines.

Great thanks Harry so as you can see a

outstanding quarter from an innovation standpoint from an operational

performance standpoint, driving our strategy in data and digital as well as

in building future platforms in cell and gene therapy and most importantly in

delivering on our mission to reimagine medicine for

patients all around the world and I'd like to thank all of our associates

around Novartis for their great commitment to our company and our

purpose to continue to deliver these medicines that change the lives of people.